Correction: ‘Multicentre, randomised, double-blind, parallel controlled trial to investigate timing of platelet inhibition after coronary artery bypass grafting: TOPCABG trial study

Yuan X, Chu Q, Chen K, et al. Multicentre, randomised, double-blind, parallel controlled trial to investigate timing of platelet inhibition after coronary artery bypass grafting: TOPCABG trial study. BMJ Open 2023;13:e070823. doi:10.1136/bmjopen-2022-070823

This article has been corrected since it was published online. The Sample size has been updated from “Primary efficacy endpoint: patency in De-DAPT group is non-inferior to DAPT group. We assumed that the 1-year SVG occlusion rate would be 10% with De-DAPT and DAPT and non-inferiority margin would be 3.0%.” to “Primary efficacy endpoint: patency in De-DAPT group is non-inferior to DAPT group. We assumed that the 1-year SVG occlusion rate would be 10% with DAPT and non-inferiority margin would be 3.5%.”

This post was originally published on https://bmjopen.bmj.com